-transparent.png){kind=logo}
Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 patients with acute lymphocytic leukemia) were treated with a new anthracycline antibiotic, aclacinomycin-A (ACM). ACM was administrated by intravenous drip infusion at a dose of 20 mg/day for 7 or 14 days and this was repeated after at least 7 days. Four of 12 patients (33.3%) achieved a complete remission; 3 of 7 acute myelocytic leukemia (42.8%) and 1 of 5 acute lymphocytic leukemia (20.0%). The days required for achieving the complete remission ranged from 23 to 78 days (median: 61) and the total doses of ACM used from 180 to 500 mg (median: 310), and the durations of complete remission from 11 to 28+ weeks (median: 21+). The untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological toxicities were frequently seen; however, they were controlled by supportive treatment. Alopecia was not observed. Arrythmia was recognized in one patient at the initiation of ACM infusion with complete remission without withdrawal of ACM. These results suggest that ACM is a potentially effective anthracycline antibiotic in the clinical management of acute leukemia.
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
December 1989,
Bone marrow transplantation,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
January 1992,
Anticancer research,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
January 1989,
Hematological oncology,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
December 2012,
Annals of hematology,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
January 1986,
Acta Universitatis Palackianae Olomucensis Facultatis Medicae,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
January 1987,
Haematology and blood transfusion,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
September 1994,
Leukemia research,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
March 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
January 1984,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
I Takahashi, and
M Hara, and
T Adachi, and
K Takaoka, and
M Sakano, and
M Lai, and
F Kohi, and
S Yorimitsu, and
M Tokioka, and
K Kitajima, and
I Kimura, and
H Sanada
January 2014,
Pakistan journal of medical sciences,
